Cyto-Facto
Signal active
Organization
Contact Information
Overview
Cyto-Facto is a biotechnology company that develops and manufactures CAR-T cell therapies and mesenchymal stem cell products.
About
Industries
Biotechnology, Manufacturing, Therapeutics
Founded
2022
Employees
51-100
Headquarters locations
Asia
Social
N/A
Profile Resume
Cyto-Facto headquartered in Asia, operates in the Biotechnology, Manufacturing, Therapeutics sector. The company focuses on Biotechnology and has secured $91.5M in funding across 12 round(s). With a team of 51-100 employees, Cyto-Facto is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Cyto-Facto, raised $7.6M. Discover more about their projects, partnerships, and impact on our platform.
Employees
N/A
Funding Rounds
Funding rounds
1
Investors
7
Lead Investors
0
Total Funding Amount
$7.6M
Details
1
Cyto-Facto has raised a total of $7.6M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2024 | Early Stage Venture | 7.6M |
Investors
Cyto-Facto is funded by 10 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Cyto-Facto | - | FUNDING ROUND - Cyto-Facto | 7.6M |
| D3 | - | FUNDING ROUND - D3 | 7.6M |
| Cyto-Facto | - | FUNDING ROUND - Cyto-Facto | 7.6M |
| SMBC Venture Capital | - | FUNDING ROUND - SMBC Venture Capital | 7.6M |
Recent Activity
There is no recent news or activity for this profile.